Photodynamic therapy for neovascular age-related macular degeneration

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Wormald, Richard ^a   Evans, Jennifer R ^a   Smeeth, Liam L ^a   Henshaw, Katherine S ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

*Photochemotherapy; Glucose therapeutic use ; Humans; Macular degeneration complications; *drug therapy ; Photosensitizing agents *therapeutic use ; Porphyrins *therapeutic use ; Randomized controlled trials as topic; Retinal neovascularization *drug therapy

Indexed keywords

VERTEPORFIN;

ALLERGIC REACTION; BACKACHE; CLINICAL TRIAL; DEATH; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; INFUSION RELATED BACK PAIN; INJECTION SITE REACTION; LASER; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; RETINA CAPILLARY NONPERFUSION; RETINA HEMORRHAGE; RETINA ISCHEMIA; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL DISORDER; VITREOUS HEMORRHAGE;

EID: 77950208140     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Schmidt-Erfurth 2008 {published data only} Michels S, Wachtlin J, Gamulescu MA, Heimann H, Prünte C, Inhoffen W, et al.Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration. Ophthalmology 2005;112(12):2070-5.
2. * Schmidt-Erfurth U, Sacu S, the Early Retreatment Study Group. Randomized multicenter trial of more intense and standard early verteporfin treatment of neovascular age-related macular degeneration. Ophthalmology 2008;115(1):134-40.
3. TAP 1999 {published and unpublished data} Rubin GS, Bressler NM, the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Effects of verteporfin therapy on contrast sensitivity: results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation - TAP report no. 4. Retina 2002;22(5):536-44.
4. * Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials - TAP report 1. Archives of Ophthalmology 1999;117(10):1329-45.
5. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Two-year results of 2 randomized clinical trials - TAP report 2. Archives of Ophthalmology 2001;119(2):198-207.
6. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials - TAP report no 5. Archives of Ophthalmology 2002;120(10):1307-14.
7. Valio 2007 {published data only} * Rosenfeld PJ, Boyer DS, Bressler NM, Fish G, Sanderson Grizzard W, Hao Y, et al. The VALIO Study Group. Verteporfin therapy of subfoveal occult choroidal neovascularization in AMD using delayed light application: one-year results of the VALIO Study. American Journal of Ophthalmology 2007;144(6): 970-2.
8. VIM 2005 {published data only} Azab M, Boyer DS, Bressler NM, Bressler SB, Cihelkova I, Hao Y, et al. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration. Archives of Ophthalmology 2005;123(4):448-57.
9. VIO 2007 {published and unpublished data} Altaweel MM, Hiner C, VIO Study Group. Baseline CNV lesion characteristics in the Visudyne in Occult (VIO) trial: comparison between fluorescein angiography and ICG. Investigative Ophthalmology & Visual Science 2004;45:E- Abstract 3160.
10. European Medicines Agency (EMEA). Product Name: VISUDYNE Procedure no:EMEA/H/C/000305/II/0053. http://www.emea.europa.eu/humandocs/PDFs/EPAR/ Visudyne/H-305-II-53-AR.pdf 5th June 2007.
11. Kaiser PK, VIO Study Group. Verteporfin In Occult (VIO): the design of a phase III controlled clinical trial of verteporfin therapy for occult with no classic subfoveal CNV secondary to AMD. Investigative Ophthalmology & Visual Science 2004;45:E abstract 2276.
12. * Kaiser PK. Visudyne in Occult CNV (VIO ) study group. Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. Current Medical Research and Opinion 2009;25(8):1853-60.
13. Retinal Physician. AMD Treatment Choices for Today and Tomorrow. Verteporfin and pegaptanib lead, with a pipeline of new possibilities under investigation. http://www.retinalphysician.com/article.aspx?article=100074 (accessed 22 May 2007).
14. VIP 2001 {published data only} Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin In Photodynamic Therapy Report 2. American Journal of Ophthalmology 2002;133(1):168-9.
15. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001;108(1):841-52.
16. * Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy Report 2. American Journal of Ophthalmology 2001;131(5):541-60.
17. ADD-V {published data only (unpublished sought but not used)} Southeastern Retina Associates. Currently enrolling clinical trials. www.tennesseeretina.com/news (accessed 22 May 2007).
18. Japan 2003 {published data only} The Japanese Age-Related Macular Degeneration Trial (JAT) Study Group. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. American Journal of Ophthalmology 2003;136(6):1049-61.
19. Schmidt-Erfurth 1999 {published data only} Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, et al.Photodynamic therapy with verteporfin for choroidal neovascularisation caused by age-related macular degeneration. Results of retreatment in a phase 1 and 2 study. Archives of Ophthalmology 1999;117(9):1177-87.
20. VER 2004 {published data only (unpublished sought but not used)} Stur M. Verteporfin Early Retreatment (VER) - 12-months results of a phase IIIb controlled clinical trial. Spektrum Der Augenheilkunde 2004;18(2):108-9.
21. Stur M, Ergun E, VER Study Group. Verteprofin Early Retreatment (VER) - 24-month results of a phase IIIB controlled clinical trial. The Macula Society. 2005:74.
22. Stur M, VER Study Group. Rationale for and design of the Visudyne in Early Retreatment (VER) trial. Investigative Ophthalmology & Visual Science 2001;42:Abstract 2382.
23. Stur M, VER Study Group. Verteporfin Early Retreatment (VER) - 12-month results of a phase IIIb controlled clinical trial. Investigative Ophthalmology & Visual Science 2004;45:Abstract 2275.
24. Armbrecht 2004 Armbrecht AM, Aspinall PA, Dhillon B. A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration. British Journal of Ophthalmology 2004;88(10):1270-3.
25. Arnold 2004 Arnold JJ, Blinder KJ, Bressler NM, Bressler SB, Burdan A, Haynes L, et al.Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. American Journal of Ophthalmology 2004;137(4): 683-96.
26. Azab 2004 Azab M, Benchaboune M, Blinder KJ, Bressler NM, Bressler SB, Gragoudas ES, et al.Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina 2004;24(1):1-12.
27. Barbazetto 2003 Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L, Kapetanios AD, et al.Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report No. 2. Archives of Ophthalmology 2003;121(9):1253-68.
28. Blinder 2003 Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, et al.Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. American Journal of Ophthalmology 2003;136(3):407-18.
29. Borodoker 2002 Borodoker N, Spaide RF, Maranan L, Murray J, Freund KB, Slakter JS, et al.Verteporfin infusion-associated pain. American Journal of Ophthalmology 2002;133(2):211-4.
30. Bressler 2002 Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, et al.Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Archives of Ophthalmology 2002;120(11): 1443-54.
31. Bressler 2004a Bressler SB, Pieramici DJ, Koester JM, Bressler M. Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevant to management - TAP report No. 6. Archives of Ophthalmology 2004; 122(3):325-9.
32. Bressler 2004b Bressler NM, VAM Study Writing Committee. Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients. Retina 2004;24(4):512-20.
33. Do 2004 Do DV, Bressler NM, Bressler SB. Large submacular hemorrhages after verteporfin therapy. American Journal of Ophthalmology 2004;137(3):558-60.
34. Glanville 2006 Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
35. Higgins 2006 Higgins JPT, Green S, editors. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Section 6. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
36. Higgins 2008 Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
37. Holz 2003 Holz FG, Jorzik J, Schutt F, Flach U, Unnebrink K. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). Ophthalmology 2003;110(2):400-5.
38. Hopley 2004 Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. British Journal of Ophthalmology 2004;88(8):982-7.
39. Kaiser 2006 Kaiser PK. Verteporfin therapy of subfoveal choroidal neovascularization in age related macular degeneration: 5-year results of two randomized clincal trials with an open label extension. TAP report No. 8. Graefe's Archive of Clinical and Experimental Ophthalmology 2006;244(9):1132-42.
40. Meads 2004 Meads C, Hyde C. Photodynamic therapy with verteporfin is effective, but how big is its effect? Results of a systematic review. British Journal of Ophthalmology 2004;88(2):212-7.
41. Miller 1999 Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, et al.Photodynamic therapy with verteporfin for choroidal neovascularisation caused by age-related macular degeneration. Results of a single treatment in a phase 1 and 2 study. Archives of Ophthalmology 1999;117(9):1161-73.
42. MPS 1994 Macular photocoagulation study group. Laser photocoagulation for juxtafoveal choroidal neovascularization: five year results from randomized clinical trials. Archives of Ophthalmology 1994;112(4): 500-9.
43. Pieramici 2006 Writing committee for the VIP Study Group. Occult with no classic subfoveal choroidal neovascular lesions in age-related macular degeneration. VIP report no. 4. Archives of Ophthalmology 2006;124(5):660-4.
44. Schmidt-Erfurth 2003 Schmidt-Erfurth UM, Michels S. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. Ophthalmology 2003;110(7):1306-14.
45. Schmidt-Erfurth 2004 Schmidt-Erfurth UM, Elsner H, Terai N, Benecke A, Dahmen G, Michels SM. Effects of verteporfin therapy on central visual field function. Ophthalmology 2004;111(5):931-9.
46. Woodburn 2002 Woodburn KW, Engelman CJ, Blumenkranz MS. Photodynamic therapy for choroidal neovascularization: a review. Retina 2002;22 (4):391-405.